Research ExplorerPublicationsUpdate Breast Cancer 2019 Part 1 - Implementation of Study R...

Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer

Standard

Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. / Hartkopf, Andreas D; Müller, Volkmar; Wöckel, Achim; Lux, Michael P; Janni, Wolfgang; Nabieva, Naiba; Taran, Florin-Andrei; Ettl, Johannes; Lüftner, Diana; Belleville, Erik; Schütz, Florian; Fasching, Peter A; Fehm, Tanja N; Kolberg, Hans-Christian; Overkamp, Friedrich; Schneeweiss, Andreas; Tesch, Hans.

In: GEBURTSH FRAUENHEILK, Vol. 79, No. 3, 03.2019, p. 256-267.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hartkopf, AD, Müller, V, Wöckel, A, Lux, MP, Janni, W, Nabieva, N, Taran, F-A, Ettl, J, Lüftner, D, Belleville, E, Schütz, F, Fasching, PA, Fehm, TN, Kolberg, H-C, Overkamp, F, Schneeweiss, A & Tesch, H 2019, 'Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer', GEBURTSH FRAUENHEILK, vol. 79, no. 3, pp. 256-267. https://doi.org/10.1055/a-0842-6614

APA

Hartkopf, A. D., Müller, V., Wöckel, A., Lux, M. P., Janni, W., Nabieva, N., Taran, F-A., Ettl, J., Lüftner, D., Belleville, E., Schütz, F., Fasching, P. A., Fehm, T. N., Kolberg, H-C., Overkamp, F., Schneeweiss, A., & Tesch, H. (2019). Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. GEBURTSH FRAUENHEILK, 79(3), 256-267. https://doi.org/10.1055/a-0842-6614

Vancouver

Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Nabieva N et al. Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. GEBURTSH FRAUENHEILK. 2019 Mar;79(3):256-267. https://doi.org/10.1055/a-0842-6614

Bibtex

@article{bf1a615d4d6d4b168a711614660a80ff,
title = "Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer",
abstract = "For many years, small but significant advancements have been made time and again in the prevention and treatment of early breast cancer. The so-called panel gene analyses are becoming more and more important in prevention, since the risk due to the tested genes is better understood and as a result, concepts for integration in health care can be developed. In the adjuvant situation, the first study in the so-called post-neoadjuvant situation was able to demonstrate a clear improvement in the prognosis with an absent pathological complete remission following trastuzumab or pertuzumab + trastuzumab. Additional studies with this post-neoadjuvant therapeutic concept are still being conducted at present. The CDK4/6 inhibitors which had shown a significant improvement in progression-free survival in a metastatic situation are currently being tested in the adjuvant situation in large therapeutic studies. These and other new data for the treatment or prevention of primary breast cancer are presented in this review against the backdrop of current studies.",
author = "Hartkopf, {Andreas D} and Volkmar M{\"u}ller and Achim W{\"o}ckel and Lux, {Michael P} and Wolfgang Janni and Naiba Nabieva and Florin-Andrei Taran and Johannes Ettl and Diana L{\"u}ftner and Erik Belleville and Florian Sch{\"u}tz and Fasching, {Peter A} and Fehm, {Tanja N} and Hans-Christian Kolberg and Friedrich Overkamp and Andreas Schneeweiss and Hans Tesch",
year = "2019",
month = mar,
doi = "10.1055/a-0842-6614",
language = "English",
volume = "79",
pages = "256--267",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "3",

}

RIS

TY - JOUR

T1 - Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer

AU - Hartkopf, Andreas D

AU - Müller, Volkmar

AU - Wöckel, Achim

AU - Lux, Michael P

AU - Janni, Wolfgang

AU - Nabieva, Naiba

AU - Taran, Florin-Andrei

AU - Ettl, Johannes

AU - Lüftner, Diana

AU - Belleville, Erik

AU - Schütz, Florian

AU - Fasching, Peter A

AU - Fehm, Tanja N

AU - Kolberg, Hans-Christian

AU - Overkamp, Friedrich

AU - Schneeweiss, Andreas

AU - Tesch, Hans

PY - 2019/3

Y1 - 2019/3

N2 - For many years, small but significant advancements have been made time and again in the prevention and treatment of early breast cancer. The so-called panel gene analyses are becoming more and more important in prevention, since the risk due to the tested genes is better understood and as a result, concepts for integration in health care can be developed. In the adjuvant situation, the first study in the so-called post-neoadjuvant situation was able to demonstrate a clear improvement in the prognosis with an absent pathological complete remission following trastuzumab or pertuzumab + trastuzumab. Additional studies with this post-neoadjuvant therapeutic concept are still being conducted at present. The CDK4/6 inhibitors which had shown a significant improvement in progression-free survival in a metastatic situation are currently being tested in the adjuvant situation in large therapeutic studies. These and other new data for the treatment or prevention of primary breast cancer are presented in this review against the backdrop of current studies.

AB - For many years, small but significant advancements have been made time and again in the prevention and treatment of early breast cancer. The so-called panel gene analyses are becoming more and more important in prevention, since the risk due to the tested genes is better understood and as a result, concepts for integration in health care can be developed. In the adjuvant situation, the first study in the so-called post-neoadjuvant situation was able to demonstrate a clear improvement in the prognosis with an absent pathological complete remission following trastuzumab or pertuzumab + trastuzumab. Additional studies with this post-neoadjuvant therapeutic concept are still being conducted at present. The CDK4/6 inhibitors which had shown a significant improvement in progression-free survival in a metastatic situation are currently being tested in the adjuvant situation in large therapeutic studies. These and other new data for the treatment or prevention of primary breast cancer are presented in this review against the backdrop of current studies.

U2 - 10.1055/a-0842-6614

DO - 10.1055/a-0842-6614

M3 - SCORING: Journal article

C2 - 30880824

VL - 79

SP - 256

EP - 267

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 3

ER -